# Cyril H. Benes

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/cyril-h-benes/

## Facts

| Field | Value |
| --- | --- |
| Citations | 32,250 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 76 |
| i10-index | 138 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5060699951 |
| ORCID iD | https://orcid.org/0000-0002-8751-9707 |
| Works | 691 |

## Researcher papers

- [Systematic identification of genomic markers of drug sensitivity in cancer cells](https://scholariq.org/papers/systematic-identification-of-genomic-markers-of-drug-sensitivity-in-cancer-cells/)
- [Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers](https://scholariq.org/papers/mechanisms-of-acquired-crizotinib-resistance-in-alk-rearranged-lung-cancers/)
- [Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer](https://scholariq.org/papers/molecular-mechanisms-of-resistance-to-first-and-second-generation-alk-inhibitors/)
- [Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK](https://scholariq.org/papers/therapeutic-strategies-to-overcome-crizotinib-resistance-in-non-small-cell-lung/)
- [Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models](https://scholariq.org/papers/synthetic-lethal-interaction-of-combined-bcl-xl-and-mek-inhibition-promotes/)
- [BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors](https://scholariq.org/papers/bim-expression-in-treatment-naive-cancers-predicts-responsiveness-to-kinase/)
- [PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer](https://scholariq.org/papers/pten-loss-mediates-clinical-cross-resistance-to-cdk4-6-and-pi3k-inhibitors-in/)
- [Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms](https://scholariq.org/papers/three-subtypes-of-lung-cancer-fibroblasts-define-distinct-therapeutic-paradigms/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.